-
AASLD 2024丨Dr. Jie Li and Dr. Li Zhu: PRO-C3 and GP73 Combined Non-Invasive Fibrosis Score Wins Poster of Distinction
Liver fibrosis is a crucial determinant for initiating antiviral therapy in chronic hepatitis B (CHB) patients. PRO-C3, a biomarker reflecting liver fibrosis extent, and GP73, a glycoprotein overexpressed in liver…
-
The 66th American Society of Hematology Annual Meeting (ASH)
The 66th American Society of Hematology Annual Meeting (ASH) was grandly held in San Diego, USA, from December 7th to 10th, 2024. This annual event is one of the most influential scientific communication platforms in the field of hematology worldwide. This edition of the ASH Annual Meeting attracted over 25,000 professionals, including clinicians, scientists, researchers,…
-
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West
Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC…
-
CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients
With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of…
-
An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer
On November 23rd, Dr. Tianshu Liu’s team from Zhongshan Hospital published a study titled “Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial” in JNCI Cancer Spectrum(IF=3.4). The PRESERVE 1 trial sheds light on trilaciclib’s potential to reduce chemotherapy-related toxicity in mCRC. While its efficacy in mitigating myelosuppression…
-
AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations
Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment in the field. Current HCC screening techniques primarily rely on abdominal ultrasound (US) and alpha-fetoprotein (AFP) testing. However, these methods have limitations: the accuracy of…
-
CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.
-
CCHIO 2024 | Dr. Dingzhi Huang: Advances in Small Cell Lung Cancer (SCLC) Treatment
At the 2024 CCHIO Lung Tumor Integrated Rehabilitation Session, Dr. Dingzhi Huang from Tianjin Medical University Cancer Institute and Hospital delivered a presentation titled “Advances in SCLC Treatment.” Below is a comprehensive summary of the key highlights.
Connecting Medical Expertise through Media